Cytomegalovirus Infection Clinical Trial
Official title:
A Phase 1 Clinical Trial to Evaluate the Safety of, and Kinetics and Magnitude of the CMV-Specific Immune Response to, Challenge With a Live Attenuated Strain of CMV (Towne) in Healthy, CMV- Seronegative, Adult Subjects Who Previously Received a CMV Immunotherapeutic Trivalent pDNA Vaccine (VCL CT02) Administered Intradermally or Intramuscularly
Objectives of this trial are to:
1. Evaluate the kinetics and magnitude of the CMV-specific immune response post-Towne
challenge (3000 pfu) in healthy CMV-seronegative volunteers who received VCL CT02
administered ID or IM 9 to 15 months previously as measured by: 1) ELISA and/or
virus-neutralizing antibody titers for gB; 2) T-cell IFN-g ELISPOT; 3) T-cell
proliferation assays (CFSE) for IE1, pp65, and/or gB; and possibly 4) cytokine and
phenotypic flow cytometry responses to pp65, IE1, and/or gB.
2. Evaluate the safety safety of Towne challenge in healthy CMV-seronegative adult
subjects who have previously been immunized with a trivalent pDNA CMV vaccine
(VCL-CT02) administered intramuscularly (IM) or intradermally (ID).
Our hypothesis is that the immune response to Towne vaccine 3000 pfu challenge after
VLC-CT02 priming will be greater than that after Towne vaccination alone (concurrent
controls will be administered Towne alone in a concurrent, companion trial).
This is a Phase 1, single-center, open-label trial of the live, attenuated Towne CMV vaccine
administered as a “challenge” to healthy, CMV-seronegative, adult subjects who previously
received the CMV immunotherapeutic trivalent pDNA-based vaccine, VCL-CT02, given by
intradermal or intramuscular routes as described in the following table; these subjects have
been followed for 32 weeks.
Table 6.1 Subject Distribution Group Formulation Dosing Regimen (day) Dose per
Injection(Administered to the deltoid region) Route of Administration Number of Subjects
1. VCL-CT02 0, 28, 56 1.0 mg Intramuscular (IM) 6
2. VCL-CT02 0, 28, 56 100 μg/injection × 2 injections Intradermal (ID) 11 Total 17
Up to 10 subjects from Groups 1 and 2 will be approached for enrollment in the current
protocol. If a subject consents and meets all eligibility criteria, the subject will receive
Towne (3000 pfu subcutaneously) between 9 and 15 months after the subject’s first dose of
VCL-CT02. Safety will be monitored and Both antibody to CMV gB and T-cell responses to CMV
antigens will be measured at specified intervals for 252 days post Towne challenge.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00023036 -
Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
|
||
Terminated |
NCT01037712 -
In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir
|
Phase 4 | |
Completed |
NCT01552369 -
CMV Antiviral Prevention Strategies in D+R-Liver Transplants ("CAPSIL")
|
Phase 4 | |
Completed |
NCT01588015 -
Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
|
Phase 1 | |
Completed |
NCT00223925 -
Maribavir for Prevention of CMV After Stem Cell Transplants
|
Phase 2 | |
Active, not recruiting |
NCT05085366 -
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
|
Phase 3 | |
Completed |
NCT01220895 -
Alternate Donor Study of Pre-Emptive Cellular Therapy
|
Phase 2 | |
Completed |
NCT00942305 -
Study of CMX001 to Prevent/Control Cytomegalovirus Infection in R+ Hematopoietic Stem Cell Transplant Recipients
|
Phase 2 | |
Completed |
NCT00373412 -
Trial of pDNA CMV Vaccine (VCL-CT02) Followed by Towne CMV Vaccine (Towne) Challenge
|
Phase 1 | |
Completed |
NCT05105048 -
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus (CMV) Vaccine mRNA-1647
|
Phase 1 | |
Completed |
NCT00386412 -
TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
|
Phase 2 | |
Completed |
NCT03382405 -
Safety, Reactogenicity, and Immunogenicity of Cytomegalovirus Vaccines mRNA-1647 and mRNA-1443 in Healthy Adults
|
Phase 1 | |
Completed |
NCT02454699 -
Safety and PK of MBX-400 (Cyclopropavir) in Normal Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03910478 -
Dried Blood Spot Testing of CMV Detection in HCT Recipients
|
N/A | |
Completed |
NCT01354301 -
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate
|
Phase 4 | |
Active, not recruiting |
NCT01473849 -
Impact of Cytomegalovirus (CMV) Replication Over Hepatitis C Recurrence in Liver Transplant Recipients
|
N/A | |
Completed |
NCT00880789 -
Safety, Toxicity and MTD of One Intravenous IV Injection of Donor CTLs Specific for CMV and Adenovirus
|
Phase 1 | |
Completed |
NCT00817908 -
Quantiferon - Cytomegalovirus (CMV) and the Prediction of CMV Infection In High Risk Solid Organ Transplant Recipients
|
N/A | |
Completed |
NCT00273143 -
A Trial to Study How the Body Fights Off Cytomegalovirus (CMV) in Hematopoietic Transplant Recipients.
|
Phase 1 | |
Completed |
NCT00194155 -
Cytomegalovirus (CMV) Infection in Pregnancy
|
N/A |